Robert F. Ryan, MS, Ph.D., Strives to Establish Novel Effective Living Cell-Based Treatment for Pancreatic Cancer

    SILVER SPRING, MD, December 20, 2013 /24-7PressRelease/ -- Chief Scientific Officer of Nuvilex, Incorporated (OTCQB: NVLX), Dr. Robert F. Ryan, having completed his first three years at Nuvilex as President and Chief Executive Officer, was recently named a VIP member of Worldwide Branding. This special distinction honors individuals who have shown exceptional commitment to achieving personal and professional success.

Recognizing the importance of a strong educational foundation, Dr. Ryan completed his post-doctoral Fellowships with the National Cancer Institute and the National Institutes of Child Health and Human Development, both within the National Institutes of Health and also one fellowship at The Wistar Institute. He had previously achieved a Ph.D. in human molecular genetics and cellular and molecular biology from Thomas Jefferson University, a master's degree in biochemistry and cellular and molecular biology at Medical College of Georgia, and a bachelor's degree in biochemistry at Clemson University. Drawing on his educational accomplishments, Dr. Ryan embarked on a career in biochemistry which has spanned more than 30 years.

For the past three years, Dr. Ryan has focused his efforts on creating an emerging biotech company at Nuvilex, Incorporated. The company works internationally to advance therapies as a developer of cell therapy solutions. Ever eager to increase healthy populations and formulate natural products, Nuvilex, Incorporated has succeeded in working to advance a treatment against inoperable pancreatic cancer.

Nuvilex, Inc. during Dr. Ryan's guidance recently completed an acquisition of Bio Blue Bird AG (BBB) and having secured multiple fundings through the sale of restricted stock. The funds have been allocated for completing the acquisition of BBB, paving the way for Nuvilex's future planned late stage clinical trials in pursuit of a treatment for pancreatic cancer. In addition, a licensing contract with Austrianova will enable Nuvilex to complete preclinical testing on diabetic animals and eventually clinical trials in humans. Ever eager to become the worldwide leader of cell therapy solutions for treating cancer and diabetes, Nuvilex plans to integrate and implement new clinical trials, research, and studies for pancreatic cancer in the coming years. Regarding the latter licensing rights, Dr. Ryan has been quoted as saying, "We are pleased to have secured this critical financing that has now enabled us to acquire the worldwide rights for the cellulose-based, live-cell encapsulation technology for the development of diabetes treatments. This acquisition is a major step in the continuing evolution of Nuvilex as a biotechnology company focused on live-cell encapsulation for the treatment of cancer and diabetes." Dr. Ryan also stated to Worldwide Branding, "Through work and partnering with Austrianova, Austrianova Singapore, ViruSure, Thermo Fisher and Inno Biologics, and additional companies in the future, Nuvilex expects to reach its company and clinical goals and objectives."

Nuvilex, Incorporated is working with Inno Biologics on cloning the cancer treatment cells through a specialized cell cloning procedure as part of its overall development plan. At the heart of the operation is Dr. Robert Ryan. He stated that he selected Inno Biologics, a cGMP compliant company located in Malaysia, to carry out the critical initial cell cloning for the project, utilizing only the most stringent criteria. In preparing for future clinical trials, Dr. Ryan is supervising the entire operation with qualified staff under the most stringent conditions.

Responsible for overseeing the company's operations for the past three years, Dr. Ryan worked to ensure accurate SEC documentation submissions and filings and has met with companies and researchers around the globe. Proficient in cell and molecular biology, he has also been focused on working closely with the Nuvilex teams to ensure completed contracts, debt settlements, and accurate investor documentation. As part of his move in becoming the Chief Scientific Officer at Nuvilex, Dr. Ryan indicated in the coming years, he will play the integral role in the advancement of research for pancreatic cancer at Nuvilex and continue to implement and finalize a complete turnaround of the company, having helped rescue Nuvilex from bankruptcy prior to his arrival and provide the impetus for the reversal of the stock from approximately $0.007 in 2010 prior to his arrival to a recent high of $0.220 due as he states, "to the teamwork of the individuals within and associated with the company." Dr. Ryan told Worldwide Branding, "It is my aim to strive to bring a cell-based therapy to become an effective treatment for patients with advanced, inoperable pancreatic cancer in the coming years."

About Worldwide Branding
For over 15 years, Worldwide Branding has been the leading, one-stop-shop, personal branding company, both in the United States and abroad. From writing professional biographies and press releases, to creating and driving traffic to personal websites, our team of branding experts tailor each product specifically for our clients needs. We are dedicated to empowering our 600,000 clients with effective branding tools to help them achieve success. From healthcare to finance to education and law, our constituents represent every major industry and occupation, at all career levels.

An international company, we provide our members with access to members in over 52 countries including, the United States, Canada, Australia, the United Kingdom, France, The Netherlands, Germany, Ireland, Spain, Switzerland, South Africa, Belgium, Mexico, Italy, Brazil, Sweden and The United Arab Emirates, just to name a few.

We presently have two offices, but we are headquartered on Long Island. Our team comprises more than 100 staff members and spans 10 key departments.

For more information, please visit http://www.worldwidebranding.com.

Contact:
Ellen Campbell
Director, Media Relations
[email protected]

# # #